Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12624815 | 0.91 | RARB (0.40) | GRM2ALOX5APFEN1FFAR4FFAR1 | |
| SCHEMBL20118150 | 0.90 | GRM2 (0.36) | GRM2ALOX5APFEN1FFAR4FFAR1 | |
| SCHEMBL2483680 | 0.90 | GRM2 (0.36) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL3439584 | 0.90 | GRM2 (0.36) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL19829192 | 0.89 | FFAR1 (0.35) | GRM2ALOX5APFEN1FFAR4FFAR1 | |
| SCHEMBL12624826 | 0.89 | RARB (0.36) | GRM2ALOX5APFEN1FFAR4FFAR1 | |
| SCHEMBL15304009 | 0.89 | GRM2 (0.36) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL15304006 | 0.89 | GRM2 (0.36) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL18310587 | 0.88 | FFAR1 (0.34) | GRM2ALOX5APFEN1FFAR4FFAR1 | |
| SCHEMBL18162336 | 0.88 | ALOX5AP (0.40) | GRM2ALOX5APFEN1FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304784-A1 | LIQUID CRYSTAL MEDIUM, OPTICAL DEVICE AND LIQUID CRYSTAL COMPOUND | JNC CORPORATION (JP) | 2016-10-20 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | CFB, CFD, LCT | GRM2 2881/4885ALOX5AP 1014/4885FEN1 3980/4885 |
| US-20160304784-A1 | LIQUID CRYSTAL MEDIUM, OPTICAL DEVICE AND LIQUID CRYSTAL COMPOUND | HCN1, PIEZO1, NCS1 | GRM2 1606/4885ALOX5AP 2522/4885FEN1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.